Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. However, because CDKN2A encodes two distinct cell cycle inhibitory proteins, p16INK4a and p14ARF (p19Arf in mice), the mechanism of tumour suppression by CDKN2A has remained controversial. Genetic disruption of Cdkn2a(p19Arf) (hereafter Arf) alone predisposes mice to tumorigenesis, demonstrating that Arf is a tumour-suppressor gene in mice. We mutated mice specifically in Cdkn2a(p16Ink4a) (hereafter Ink4a). Here we demonstrate that these mice, designated Ink4a*/*, do not show a significant predisposition to spontaneous tumour formation within 17 months. Embryo fibroblasts derived from them proliferate normally, are mortal, and are not transformed by oncogenic HRAS. The very mild phenotype of the Ink4a*/* mice implies that the very strong phenotypes of the original Ink4a/ArfDelta2,3 mice were primarily or solely due to loss of Arf. However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. Treatment of these mice with the carcinogen 7,12-dimethylbenzanthracene (DMBA) results in an increased incidence of melanoma, with frequent metastases. Our results show that, in the mouse, Ink4a is a tumour-suppressor gene that, when lost, can recapitulate the tumour predisposition seen in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“For example, mouse embryonic fibroblasts (MEFs) lacking p53 [72] but not Ink4a (p16) or RB [73,74,75] escape Ras-induced senescence.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [74]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“MEFs mutated in components of the Rb1 or Trp53 pathways are defective in various aspects of proliferative control, displaying altered proliferation rates, cell-cycle distributions and cell size compared with wild-type cell”
BackgroundTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 1×
“No melanomas were observed in DMBA-treated control animals, either in those followed by us for 8 months or in historical control”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206 · cited 1×
“p16 INK4a and its downstream targets, the RB1 family members, have been implicated in this response in both huma”
BackgroundBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
Self-citationThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Cited by
Items 301–400 of 567
Targeting senescent cells for the treatment of age-associated diseases
Suda, M., Tchkonia, T., Kirkland, J. L., & Minamino, T. (2024) · The Journal of Biochemistry · doi:10.1093/jb/mvae091 · Cited by 39
Tury, A., Mairet‐Coello, G., & DiCicco-Bloom, E. M. (2012) · Developmental Neurobiology · doi:10.1002/dneu.20999 · Cited by 34
Camacho, C. V., Todorova, P. K., Hardebeck, M. C., Tomimatsu, N., del Alcazar, C. R. G., Ilcheva, M., Mukherjee, B., Mcellin, B. M., Vemireddy, V., Hatanpaa, K. J., et al. (2014) · Oncogene · doi:10.1038/onc.2014.29 · Cited by 33
Trp53 Deletion Stimulates the Formation of Metastatic Pancreatic Tumors
Morton, J. P., Klimstra, D. S., Mongeau, M. E., & Lewis, B. C. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070778 · Cited by 33
Wangari‐Talbot, J., & Chen, S. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2012.00330 · Cited by 42
“Studies have shown that inactivation of p16Ink4a increased susceptibility to both spontaneous and carcinogen-induced melanoma (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundYao, J., Zhang, L., Zhang, X., He, Z., Ma, Y., Hui, L., Wang, X., & Hu, Y. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077974 · Cited by 31
Cyclin-dependent kinase inhibitors in malignant hematopoiesis
Schirripa, A., Sexl, V., & Kollmann, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.916682 · Cited by 41
“Of note, the concomitant heterozygous loss of p19 in p16 animals increases tumorigenesis and provokes the development of a wide spectrum of malignancies, including lymphoma (110).”
BackgroundFujiwara‐Igarashi, A., Goto‐Koshino, Y., Mochizuki, H., Sato, M., Fujino, Y., Ohno, K., & Tsujimoto, H. (2014) · Research in Veterinary Science · doi:10.1016/j.rvsc.2014.04.008 · Cited by 32
“Meanwhile, mice with a disruption of both alleles of p16 and an intact p19 have a moderately increased cancer susceptibility (Krimpenfort et al., 2001).”
BackgroundThe Role of CDKs and CDKIs in Murine Development
Campbell, G. J., Hands, E. L., & de Pette, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155343 · Cited by 37
González‐Gil, C., Ribera, J., Ribera, J., & Genescà, E. (2021) · Genes · doi:10.3390/genes12010079 · Cited by 33
“The mouse phenotype was much closer to that of double-null KO mice [119] than Cdkn2a-null mice [120,121], suggesting that the oncogenic properties associated with this locus were manly linked to the absence of the ARF gene.”
BackgroundEvidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells
Gonçalves, A. F., Adlesic, M., Brandt, S., Hejhal, T., Harlander, S., Sommer, L., Shakhova, O., Wild, P. J., & Frew, I. J. (2017) · Nature Communications · doi:10.1038/s41467-017-01514-3 · Cited by 31
Restoration of protein synthesis in pancreatic cancer cells by trans-splicing ribozymes
Kastanos, E. K., Hjiantoniou, E., & Phylactou, L. A. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.203 · Cited by 30
Aberrant expression of p14 ARF in human cancers: A new biomarker?
Inoue, K., & Fry, E. A. (2018) · Tumor and Microenvironment · doi:10.4103/tme.tme_24_17 · Cited by 33
Aveyard, J. S., & Knowles, M. A. (2004) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60532-6 · Cited by 33
David-Pfeuty, T. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.008 · Cited by 37
Modeling gene–environment interactions in malignant melanoma
Merlino, G. T., & Noonan, F. P. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00006-6 · Cited by 32
p53-independent apoptosis is induced by the p19ARF tumor suppressor
Tsuji, K., Mizumoto, K., Sudo, H., Kouyama, K., Ogata, E., & Matsuoka, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00723-4 · Cited by 35
Non-canonical functions of SNAIL drive context-specific cancer progression
Paul, M. C., Schneeweis, C., Falcomatà, C., Shan, C., Rossmeisl, D., Koutsouli, S., Klement, C., Zukowska, M., Widholz, S. A., Jesinghaus, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36505-0 · Cited by 34
Mouse melanoma models and cell lines
Damsky, W., & Bosenberg, M. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00777.x · Cited by 40
Naemura, M., Tsunoda, T., Inoue, Y., Okamoto, H., Shirasawa, S., & Kotake, Y. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2618-5 · Cited by 29
Koyama, M., Matsuzaki, Y., Yogosawa, S., Hitomi, T., Kawanaka, M., & Sakai, T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0814 · Cited by 28
Genetic Modeling of Glioma Formation in Mice
Begemann, M., Fuller, G. N., & Holland, E. C. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00428.x · Cited by 28
Lagresle, C., Gardie, B., Eyquem, S., Fasseu, M., Vieville, J.-C., Pla, M., Sigaux, F., & Bories, J.-C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2325 · Cited by 28
CIP/KIP and INK4 families as hostages of oncogenic signaling
Csergeová, L., Krbušek, D., & Janoštiak, R. (2024) · Cell Division · doi:10.1186/s13008-024-00115-z · Cited by 33
“Mice lacking two Ink4 genes, such as Cdkn2a/Cdkn2b or Cdkn2a/Cdkn2d , display increased tumor susceptibility compared to p16INK4a-null mice [182, 218].”
BackgroundInfluentialMonoclonal Antibodies to the Mouse p19 Arf Tumor Suppressor Protein
Bertwistle, D., Zindy, F., Sherr, C. J., & Roussel, M. F. (2004) · Hybridoma and Hybridomics · doi:10.1089/hyb.2004.23.293 · Cited by 30
An essential role for Ink4 and Cip/Kip cell-cycle inhibitors in preventing replicative stress
Quereda, V., Porlan, E., Cañamero, M., Dubus, P. R., & Malumbres, M. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.112 · Cited by 36
Targeting p16INK4a Promotes Lipofibroblasts and Alveolar Regeneration after Early-Life Injury
Zysman, M., Baptista, B. R., Essari, L.-A., Taghizadeh, S., de Ménonville, C. T., Giffard, C., Issa, A., Franco‐Montoya, M., Breau, M., Souktani, R., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1573oc · Cited by 29
Regulation of cellular senescence by Rb2/p130
Helmbold, H., Deppert, W., & Bohn, W. (2006) · Oncogene · doi:10.1038/sj.onc.1209613 · Cited by 33
“Rodent cells lacking p16INK4a or pRb/p105 entered Oncogene cellular senescence with the same efficiency as did the wild-type cells when transfected with an activated oncogene (Krimpenfort et al., 2001; Peeper et al., 2001; Sharpless et al., 2001).”
BackgroundModels and mechanisms in malignant melanoma
Benjamin, C. L., Melnikova, V. O., & Ananthaswamy, H. N. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20353 · Cited by 33
“spontaneous tumor formation (sarcoma, lymphoma, and melanoma) was observed in p16 / mice over p16þ/ and p16þ/þ [24].”
BackgroundDamo, L. A., Snyder, P. W., & Franklin, D. S. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20068 · Cited by 31
The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway
Martinelli, P., Bonetti, P., Sironi, C., Pruneri, G., Fumagalli, C., Raviele, P. R., Volorio, S., Pileri, S. A., Chiarle, R., McDuff, F. K. E., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301135 · Cited by 28
Woods, J. M., Kłosowska-Buryło, K., Spoden, D. J., Stumbo, N. G., Paige, D. J., Scatizzi, J. C., Volin, M. V., Rao, M. S., & Perlman, H. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1999 · Cited by 24
“Deficiencies in p16 [4,5], p18 [6], p19 [7,8], p27 [6,9-11] and p21 [12,13] may lead to or enhance oncogenesis.”
BackgroundAppleman, V. A., Ahronian, L. G., Cai, J., Klimstra, D. S., & Lewis, B. C. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0340-t · Cited by 32
p19Ink4d Is a Tumor Suppressor and Controls Pituitary Anterior Lobe Cell Proliferation
Bai, F., Chan, H. L., Smith, M. D., Kiyokawa, H., & Pei, X. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01363-13 · Cited by 27
Aguirre‐Hernández, J., Milne, B. S., Queen, C., O´Brien, P. C. M., Hoather, T. M., Haugland, S., Ferguson-Smith, M. A., Dobson, J. M., & Sargan, D. R. (2009) · BMC Veterinary Research · doi:10.1186/1746-6148-5-27 · Cited by 31
Genetics of coronary artery disease: focus on genome-wide association studies.
Baudhuin, L. M. (2009) · PubMed · Cited by 31
Sánchez‐Osuna, M., Martínez‐Escardó, L., Granados-Colomina, C., Martínez‐Soler, F., Pascual-Guiral, S., Iglesias‐Guimarais, V., Velasco, R., Plans, G., Vidal, N., Tortosa, A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov315 · Cited by 24
YB 1 binds to and represses the p16 tumor suppressor gene
Kotake, Y., Ozawa, Y., Harada, M., Kitagawa, K., Niida, H., Morita, Y., Tanaka, K., Suda, T., & Kitagawa, M. (2013) · Genes to Cells · doi:10.1111/gtc.12093 · Cited by 29
Wnt signaling and senescence: A tug of war in early neoplasia?
Adams, P. D., & Enders, G. H. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.11.6943 · Cited by 26
Physical and Functional Interaction of the p14ARF Tumor Suppressor with Ribosomes
Rizos, H., McKenzie, H. A., Ayub, A. L. P., Woodruff, S., Becker, T. M., Scurr, L. L., Stahl, J., & Kefford, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609405200 · Cited by 30
Progressive Appearance of Pigmentation in Amelanotic Melanoma Lesions
Cohen-Solal, K., Crespo‐Carbone, S. M., Namkoong, J., Mackason, K. R., Roberts, K. G., Reuhl, K. R., & Chen, S. (2002) · Pigment Cell Research · doi:10.1034/j.1600-0749.2002.02024.x · Cited by 23
Tumor Suppression for ARFicionados: The Relative Contributions of p16INK4a and p14ARF in Melanoma
Peters, G. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn156 · Cited by 24
Activation of protein kinase C promotes human cancer cell growth through downregulation of p18INK4c
Matsuzaki, Y., Takaoka, Y., Hitomi, T., Nishino, H., & Sakai, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207702 · Cited by 26
“Consistently, mice deficient in p16INK4a develop normally and are highly susceptible to malignant tumors (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundLoss of neurofibromatosis-1 and p19ARF cooperate to induce a multiple tumor phenotype
King, D., Yang, G., Thompson, M. A., & Hiebert, S. W. (2002) · Oncogene · doi:10.1038/sj.onc.1205632 · Cited by 28
“However, in mice, the specific deletion of either p16INK4a or p19ARF promotes tumorigenesis (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001). p16INK4a is a cyclindependent kinase inhibitor that is a key component of the retinoblastoma tumor suppressor pathway. p19ARF acts in…”
BackgroundMouse Models of Cell Cycle Regulators: New Paradigms
Aleem, E. A., & Kaldis, P. (2006) · Springer eBooks · doi:10.1007/400_023 · Cited by 25
A Versatile ES Cell–Based Melanoma Mouse Modeling Platform
Bok, I., Vera, O., Xu, X., Jasani, N., Nakamura, K., Reff, J., Nenci, A., Gonzalez, J. G., & Karreth, F. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2924 · Cited by 23
Ha, N., Faraji, F., & Hunter, K. W. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7876-8_17 · Cited by 31
Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models
DeCant, B. T., Principe, D. R., Guerra, C. E., di Magliano, M. P., & Grippo, P. J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00464 · Cited by 24
“In addition, the elastasetva;Trp53flox/flox;Ptf1aCre/+ mice were crossed to Ink4a/Arf flox/+ (Krimpenfort et al., 2001) mice to assess tumor development in the context of a simultaneous p53 deficiency and Ink4a/Arf single allele deletion.”
MethodMOZ and BMI1 act synergistically to maintain hematopoietic stem cells
Sheikh, B. N., Metcalf, D., Voss, A. K., & Thomas, T. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.10.006 · Cited by 24
Al‐Khalaf, H. H., Lach, B., Allam, A. A. K., Hassounah, M. I., Alkhani, A. M., Elkum, N. B., Alrokayan, S., & Aboussekhra, A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.10.074 · Cited by 23
Senescence as a modulator of oral squamous cell carcinoma development
Parkinson, E. K. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2009.09.009 · Cited by 25
Frijhoff, A. F. W., Conti, C. J., & Senderowicz, A. M. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20013 · Cited by 24
Wang, P.-Y., Young, F. M., Chen, C., Stevens, B. M., Neering, S. J., Rossi, R. M., Bushnell, T. P., Kuzin, I. I., Heinrich, D., Bottaro, A., et al. (2008) · Blood · doi:10.1182/blood-2008-02-142190 · Cited by 22
The ARF‐p16 Gene Locus in Carcinogenesis and Therapy of Head and Neck Squamous Cell Carcinoma
Yarbrough, W. G. (2002) · The Laryngoscope · doi:10.1097/00005537-200212000-00002 · Cited by 23
“Results of mice harboring a targeted p16 knockout that does not affect ARF expression have recently been presented.(53,57) Mice lacking expression of functional p16 protein also develop spontaneous tumors, but at a lower frequency and longer latency relative to ARF-deficient mice.”
BackgroundInfluentialSeoane, M., Costoya, J. A., & Arce, V. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-13408-x · Cited by 22
Hahn, W. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.007 · Cited by 23
Calbó, J., Serna, C., Garriga, J., Graña, X., & Mazo, A. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401481 · Cited by 25
Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape
Battaglia, L., Scomparin, A., Dianzani, C., Milla, P., Muntoni, E., Arpicco, S., & Cavalli, R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101617 · Cited by 23
Dissecting the Contribution of p16INK4A and the Rb Family to the Ras Transformed Phenotype
Mitchell, P. J., Pérez‐Nadales, E., Malcolm, D. S., & Lloyd, A. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.7.2530-2542.2003 · Cited by 23
Malignant Melanoma–a Genetic Overview
Bloethner, S., Scherer, D., Drechsel, M., Hemminki, K., & Kumar, R. (2009) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(09)73167-9 · Cited by 23
Regulation of p27 in the process of neuroblastoma N2A differentiation
Muñoz, J. P., Sánchez, J. R., & Maccioni, R. B. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10525 · Cited by 19
“On the other hand, the elucidation of the regulatory factors implicated in cell cycle arrest is of the utmost importance in the study of cellular anomalies involved in the pathogenesis of cancer [Kawamata et al., 1996; Li and Sun, 1998; Krimpenfort et al., 2001; Nigg, 2001].”
BackgroundA distant, cis-acting enhancer drives induction of Arf by Tgfβ in the developing eye
Zheng, Y., Devitt, C. C., Liu, J., Mei, J., & Skapek, S. X. (2013) · Developmental Biology · doi:10.1016/j.ydbio.2013.05.003 · Cited by 21
“engineered to lack Arf, Ink4a, or Cdkn2b are susceptible to a wide range of cancers as they age (Kamijo et al., 1997; Krimpenfort et al., 2001; Latres et al., 2000; Serrano et al., 1996; Sharpless et al., 2001).”
BackgroundBiochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A
Kim, D.-M., Yang, K., & Yang, B. (2003) · Experimental & Molecular Medicine · doi:10.1038/emm.2003.55 · Cited by 20
Cell cycle in sporadic melanoma
Czajkowski, R., Drewa, T. A., Woźniak, A., & Krzyżyńska‐Malinowska, E. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01601.x · Cited by 19
Loss of p16: A Bouncer of the Immunological Surveillance?
Leon, K. E., Tangudu, N. K., Aird, K. M., & Buj, R. (2021) · Life · doi:10.3390/life11040309 · Cited by 22
“Early suppression of p16 bypasses senescence in vitro and in vivo [18,42,43,93,94]; however, we demonstrated that knockdown of p16 at late time points upon oncogene-induced senescence does not bypass senescence but still decreases the expression of IL6 and CXCL8 [18], suggesting that this is uncoupled from the senesce…”
BackgroundMatsuzaki, Y., & Sakai, T. (2005) · Environmental Health and Preventive Medicine · doi:10.1007/bf02897996 · Cited by 17
Histone Chaperone Jun Dimerization Protein 2 (JDP2): Role in Cellular Senescence and Aging
Huang, Y., Saito, S., & Yokoyama, K. K. (2010) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/s1607-551x(10)70081-4 · Cited by 20
“Mouse strains with targeted deletions in p16Ink4a or Arf are tumor prone, whereas animals that lack p16Ink4a and Arf have a more severe phenotype [53,81–84].”
BackgroundBloethner, S., Hemminki, K., Thirumaran, R. K., Chen, B., Mueller-Berghaus, J., Ugurel, S., Schadendorf, D., & Kumar, R. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222597.50309.05 · Cited by 19
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis
Lu, Y., Yong-sheng, W., Feng, X., Shen, R. Z., Wang, J. H., Fallahi, M., Li, W., Yang, C., Hankey, W., Zhao, W., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci63139 · Cited by 26
“Further, there is no selection for Rb loss during Myc -driven lymphomagenesis in E μ - Myc transgenic mice (7), and selective inactivation of Ink4a does not affect MYC-driven lymphoma development (26).”
HuR Maintains a Replicative Life Span by Repressing the ARF Tumor Suppressor
Kawagishi, H., Hashimoto, M., Nakamura, H., Tsugawa, T., Watanabe, A., Kontoyiannis, D. L., & Sugimoto, M. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01277-12 · Cited by 17
Implication of the INK4a/ARF Locus in Gastroenteropancreatic Neuroendocrine Tumorigenesis
Simon, B., & Lubomierski, N. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.033 · Cited by 22
Genetic basis of pancreatic cancer
Schmid, R. M. (2002) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2002.0316 · Cited by 17
Menzies, S. W., Greenoak, G. E., Abeywardana, C. M., Crotty, K. A., & O'Neill, M. E. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23206.x · Cited by 17
Molecular mechanisms of cellular senescence and immortalization of human cells
Kiyono, T. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1623 · Cited by 19
“Both p53 activation and p16 elevation are induced in OIS, although changes in p16 appears to be less important in senescence of mouse cells [19,20] .”
BackgroundShort Hairpin RNA System to Inhibit Human p16 in Squamous Cell Carcinoma
Shin, J. J., Katayama, T., Michaud, W. A., & Rocco, J. W. (2004) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.130.1.68 · Cited by 17
“The few spontaneous tumors that form are mostly sarcomas and lymphomas, with no evidence of aerodigestive or other squamous cell carcinomas, even after exposure to a carcinogen.(11,12) The modest biological consequences of p16 loss in mice may be partially explained by studies showing differences in molecular mechanis…”
BackgroundVormer, T. L., Foijer, F., Wielders, C. L. C., & Riele, H. T. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00313-08 · Cited by 18
“In a p16 null background, the loss of one p19 allele accelerated tumorigenesis, while strikingly, the wild-type allele was retained in a subset of the tumors (25).”
BackgroundHashemi, J., Lindström, M. S., Asker, C., Platz, A., Hansson, J., & Wiman, K. G. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00027-7 · Cited by 18
Senescence: a companion in chemotherapy?
Berns, A. J. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00063-6 · Cited by 19
Self-citationp19ARF-induced p53-independent apoptosis largely occurs through BAX
Suzuki, H., Kurita, M., Mizumoto, K., Nishimoto, I., Ogata, E., & Matsuoka, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.071 · Cited by 23
Molecular genetics of acute lymphoblastic leukemia
Ferrando, A. A., Rubnitz, J. E., & Look, A. T. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.011 · Cited by 16
Florell, S. R., Thomas, J. R., & Grossman, D. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00679.x · Cited by 16
Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma
Eddy, K., & Chen, S. (2021) · Cancers · doi:10.3390/cancers13153874 · Cited by 20
Schmitz, N., Hirt, A., Aebi, M., & Leibundgut, K. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051137 · Cited by 17
Sen, M., Akeno, N., Reece, A. L., Miller, A. L., Simpson, D. S., & Wikenheiser‐Brokamp, K. A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.5 · Cited by 15
A natural WNT signaling variant potently synergizes with Cdkn2ab loss in skin carcinogenesis
Krimpenfort, P., Snoek, M., Lambooij, J.-P., Song, J., van der Weide, R. H., Bhaskaran, R., Teunissen, H., Adams, D. J., de Wit, E., & Berns, A. J. M. (2019) · Nature Communications · doi:10.1038/s41467-019-09321-8 · Cited by 15
Self-citationThe Evolution of Melanoma – Moving beyond Binary Models of Genetic Progression
Zeng, H., Judson‐Torres, R. L., & Shain, A. H. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.08.002 · Cited by 17
“Bi-allelic loss of CDKN2A promotes invasion and metastasis in vivo in genetically engineered mice as well as similar phenotypes in vitro in primary human melanocytes (Ackermann et al. 2005; Dhomen et al. 2009; Krimpenfort et al. 2001; Tyagi et al. 2017; Zeng et al. 2018).”
BackgroundThe Arp2/3 complex is critical for colonisation of the mouse skin by melanoblasts
Papalazarou, V., Swaminathan, K., Jaber‐Hijazi, F., Spence, H. J., Lahmann, I., Nixon, C., Salmerón‐Sánchez, M., Arnold, H.-H., Rottner, K., & Machesky, L. M. (2020) · Development · doi:10.1242/dev.194555 · Cited by 19
“, 2007), Cdkn2a (p16-Ink4a) (Krimpenfort et al., 2001) and Cdkn2a (p16/p19) (Serrano et al.”
Helmrich, A., Lee, S., O´Brien, P. C. M., Dörken, B., Lowe, S. W., Schröck, E., & Schmitt, C. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208600 · Cited by 16
“Interestingly, INK4a/ARFþ / mice produced lymphomas significantly faster than ARFþ / mice, although sole ablation of p16INK4a failed to accelerate myc-driven lymphomagenesis in a similar model (Krimpenfort et al., 2001).”
Haviernik, P., Schmidt, M., Hu, X., & Wolff, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206268 · Cited by 15
“…most frequently inactivated genes in cancers of many types and its definition as a tumor suppressor has been reinforced by studies of knockout mice (Krimpenfort et al., 2001; Sharpless et al., 2001), there is also evidence that p15INK4b functions as a tumor suppressor in a specific subset of…”
BackgroundMultiple domains of the mouse p19ARF tumor suppressor are involved in p53-independent apoptosis
Matsuoka, M., Kurita, M., Sudo, H., Mizumoto, K., Nishimoto, I., & Ogata, E. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00080-9 · Cited by 20
Canonical Signaling Pathways in Melanoma
Sun, L., & Arbesman, J. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.05.002 · Cited by 16
Molecular Mechanisms of Cellular Senescence
Becker, T. M., & Haferkamp, S. (2013) · InTech eBooks · doi:10.5772/54120 · Cited by 22
“Evidence form mouse models show that mouse embryonic fibroblasts (MEFs) of p16-null mice undergo a comparable number of cell divisions as wild type MEFs before entering senescence [34] [35], while in primary melanocytes, which were lentivirally transduced to express oncogenic Senescence and Senescence-Related Disorder…”
BackgroundAdvances in malignant melanoma: genetic insights from mouse and man
Kabbarah, O., & Chin, L. (2006) · Frontiers in bioscience · doi:10.2741/1849 · Cited by 18
The Yin-Yang of DNA Damage Response: Roles in Tumorigenesis and Cellular Senescence
Li, X., Xu, H., Chong-an, X., Lin, M., Song, X., Yi, F., Feng, Y., Coughlan, K. A., Cho, W., Kim, S. W., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022431 · Cited by 20
“Nevertheless, mice deficient in p16 displayed an increased incidence of tumorigenesis and loss of inactivation of p16 accounts for more than 30% of human tumors [130–133].”
BackgroundCDKN2A deregulation in fatty liver disease and its accelerative role in the process of lipogenesis
Zhang, Z., Wen, H., Peng, B., Weng, J., & Zeng, F. (2021) · The FASEB Journal · doi:10.1096/fj.202000683r · Cited by 13
UV Exposure, Genetic Targets in Melanocytic Tumors and Transgenic Mouse Models¶
de Gruijl, F. R., van Kranen, H. J., & van Schanke, A. (2004) · Photochemistry and Photobiology · doi:10.1562/2004-09-26-ir-328.1 · Cited by 12
Lazar, I., Clement, E., Carrié, L., Estève, D., Dauvillier, S., Moutahir, M., Dalle, S., Delmas, V., Andrieu‐Abadie, N., Larue, L., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.01.026 · Cited by 14
Régulation de p16INK4a, senescence et oncogenèse
Chien, W. W., & Ffrench, M. (2006) · médecine/sciences · doi:10.1051/medsci/20062210865 · Cited by 18
“Chez la souris, l’invalidation du gène INK4a, à l’inverse de celle du gène ARF, ne provoque pas l’apparition de tumeurs spontanées [16].”
Promiscuous and lineage-specific roles of cell cycle regulators in haematopoiesis.
Myatt, S. S., & Lam, E. W. ‐. (2007) · Cell Division · doi:10.1186/1747-1028-2-6 · Cited by 19
“Mice lacking p16INK4a are not predisposed to cancer, except for a small percentage of animals that develop B-cell lymphomas after a long latency [38,39].”
BackgroundMolecular Biology of Malignant Melanoma
Pons, M., Mancheño‐Corvo, P., Martín‐Duque, P., & Quintanilla, M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77574-6_20 · Cited by 12
Metadata
- Authors
- Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Berns, Anton
- Venue
- Nature
- Published
- 2001-09
- Volume
- 413
- Issue
- 6851
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2003223749
- Cited by
- 568
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 27 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 7 · 2015: 13 · 2014: 20 · 2013: 22 · 2012: 12
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- p16INK4a, CDKN2A, p14ARF, metastatic melanoma, cancer susceptibility, tumor suppressor, germline mutations, melanoma predisposition, DMBA-induced carcinogenesis, embryonic fibroblasts, mouse model
- MeSH terms
- Animals, Carcinogens, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Female, Fibroblasts, Humans, Male, Melanoma, Experimental, Proteins, Genes, ras, 9,10-Dimethyl-1,2-benzanthracene, Gene Deletion, Point Mutation, Cyclin-Dependent Kinase Inhibitor p16, Genes, p16, Genetic Predisposition to Disease, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.